Race Oncology Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAC.AX research report →
Price Chart
About the company
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer.
- CEO
- Daniel Tillett
- IPO
- 2016
- Employees
- 5
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on RAC.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $411.74M
- P/E
- -38.82
- PEG
- 0.44
- P/S
- 522.24
- P/B
- 15.67
- EV/EBITDA
- -38.01
- Div Yield
- 0.00%
- Gross Margin
- 49.76%
- Op Margin
- -1294.94%
- Net Margin
- -1190.78%
- ROE
- -47.44%
- ROIC
- -33.36%
Latest fiscal year · YoY change
- Revenue
- $6.04M+51.0%
- Gross Profit
- $5.41M+143.3%
- Op Income
- $-3,771,834
- Net Income
- $-4,787,258+65.4%
- EPS
- $-0.03+66.9%
- OCF Growth
- +52.1%
- FCF Growth
- +52.1%
- 52W High
- $4.90
- 52W Low
- $1.17
- 50D MA
- $2.15
- 200D MA
- $2.52
- Beta
- 0.82
- RSI (14)
- 51
- Avg Volume
- 106.61K
No earnings-call transcripts are available for RAC.AX yet.
- Free Float
- 65.3%
- Shares Outstanding
- 196.07M
- Float Shares
- 128.07M
Our RAC.AX coverage
Recent articles, reports, and earnings notes.
No research on RAC.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAC.AX report →Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
gurufocus.com · May 15
Daniel Tillett Purchases 100,000 Shares of Race Oncology (ASX:RAC) Stock
defenseworld.net · Feb 25
October inflation, jobs reports cancelled due to US government shutdown
proactiveinvestors.com · Nov 21
Fed may skip December cut but leave door open for January, Deutsche Bank analysts say
proactiveinvestors.com · Nov 21
Race Oncology launches new clinical programs in AML and lung cancer
proactiveinvestors.com · Nov 17
Pensana shares up as it launches new drill and testing plans for Angola rare-earth project
proactiveinvestors.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.